Board of Directors | Reagan-Udall Foundation

The Foundation is governed by a Board of Directors that includes members from academia, patient and consumer advocacy, FDA-regulated industry, health care, and other disciplines. The FDA Commissioner and the Director of the National Institutes of Health serve as ex officio and non-voting members of the Board. The federal statute that created the Foundation prohibits government control of it; the Foundation has no role in FDA’s regulatory process. Our bylaws outline the conflict of interest policies to assure that no one entity or organization has undue influence on Foundation initiatives and projects.

Learn more about the Foundation's founding Board members here.

Board of Directors

Richard L. Schilsky, MD, FACP, FSCT, FASCO | Board Chair

Adrian F. Hernandez, MD, MHS | Vice Chair and Chair, Research Committee

Lynne Zydowsky, PhD | Secretary and Chair, Development Committee

Debra L. Ness, MS | Treasurer

Edward John Allera, JD

Christie Boutte, PharmD, RPh

Sumbul Ahmad Desai, MD

David C. Fajgenbaum, MD, MBA, MSc, FCPP

Phil Febbo, MD | Chair, Governance Committee

William N. (Bill) Hait, MD, PhD (ret.)

James E.K. Hildreth, PhD, MD

Esther Krofah, MS

Phuong Khanh (PK) Morrow, MD

Richard A. Moscicki, MD

Pietro Antonio Tataranni, MD

Reed V. Tuckson, MD, FACP

Andrew C. von Eschenbach, MD

Mark McClellan, MD, PhD | Senior Advisor to the Board

Ex Officio

Robert M. Califf, MD, MACC | Commissioner of Food and Drugs, U.S. Food and Drug Administration

Monica M. Bertagnolli, MD | Director, National Institutes of Health

Staff Leadership

Susan C. Winckler, RPh, Esq. | CEO